Multiple Endocrine Neoplasia Type 2A (MEN2A)

At a Glance

Multiple Endocrine Neoplasia Type 2A (MEN2A) is a syndrome composed of medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism. Predisposition to this syndrome is caused by germline mutations in the RET proto-oncogene. Two of the clinical features of MEN2A are sufficient to diagnose MEN2, and one clinical feature, along with either a family history or a demonstrated RET mutation, is also strongly suggestive for this syndrome.

Medullary thyroid carcinoma is characterized by proliferation of calcitonin-secreting thyroid C-cells and is, typically, the first manifestation of MEN2A. Clinical features of MTC may include a thyroid nodule along with symptoms of local spread, such as hoarseness or shortness of breath. Pheochromocytoma can present as sustained or episodic hypertension, along with episodic headache, diaphoresis, palpitations, tachycardia, and anxiety. Primary hyperparathyroidism can manifest with symptoms of hypercalcemia or may be asymptomatic. Pheochromocytoma is present in approximately 50% of MEN2A patients, and primary hyperparathyroidism is seen in about 20-30%.

What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?

MTC is diagnosed by morphologic and immunohistochemical analysis of fine-needle aspirate thyroid material, and serum calcitonin should be elevated (although calcitonin may also be produced by other tumor types and is not in itself diagnostic). In the context of a positive diagnosis of MTC, the most important test to order is a genetic analysis of the RET proto-oncogene to determine if a germline mutation can be detected. Historically, a calcium challenge test was used to detect increased number of C-cells. In this assay, a rapid calcium infusion is performed and both calcium and calcitonin are measured at 0, 5, 10, 15, and 30 minutes. However, given the advent of RET mutation testing and the sensitivity of calcitonin assays, a calcium challenge is less commonly used

For the diagnosis of pheochromocytoma, fractionated metanephrines (urine and/or serum) should be ordered along with chromogranin A. Metanephrines are derived from the methylation of epinephrine and norepinephrine, and, because of their longer half-life, they represent a superior analyte for measurement than unmethylated catecholamines. Plasma metanephrines have traditionally been more difficult to measure than urine metanephrines because of their low levels; however, the advent of HPLC-mass spectrometry-based assays has significantly improved the detection limits, as well as eliminating some drug interferences (note that acetaminophen is a known interference with older HPLC-electrochemical detection).

Annual screening of MEN2A patients for fractionated metanephrine levels is clinically important for early identification of pheochromocytoma, and the age at which this begins is determined by the precise mutation in the RET proto-oncogene. Primary hyperparathyroidism can be detected by testing for serum calcium along with PTH.(Table 1)

Table 1.

Test Results Indicative of the Disorder
Calcitonin Plasma metanephrine Calcium, PTH RET protooncogene mutation testing
Increased in medullary thyroid carcinoma; FNA morphology should also be used for diagnosis of MTC Increased if a pheochromocytoma is present Increased in primary hyperparathyroidism Presence of known mutation confirms risk and can distinguish MEN2A from MEN2B

Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?

DNA testing of the RET proto-oncogene is not affected by any medications. Plasma levels of metanephrine and normetanephrine are elevated by MAO inhibitors, as well as amphetamines, epedrines, albuterol, cocaine, lidocaine, anesthetic gases, and withdrawal from a variety of sedatives. Urine metanephrines have been reported to be increased by tricyclic antidepressants and levodopa, as well as by extreme endogenous stress.

Although normetanephrine is generally increased by tricyclic antidepressants and nonselective alpha blockers, metanephrine is not affected and is a more significant analyte in the case of MEN2-associated pheochromocytoma. Chromogranin A levels may be elevated because of proton pump inhibitor (PPI) administration, as well as renal or liver failure. For any analyte measured by radioimmunoassay, recent administration of radioactive material may interfere with the results. All immunoassays may have falsely elevated values due to endogenous interfering antibodies.

What Lab Results Are Absolutely Confirmatory?

Germline testing for RET proto-oncogene mutations is the most important diagnostic study. Different mutations are associated with MEN2A and MEN2B, although both syndromes lead to a predisposition to MTC and pheochromocytoma. Given the risk of MTC, including early metastasis in approximately 15% of patients, a positive test for RET mutation in a patient or clinically unaffected family member, including young children, is a strong indication for thyroid removal with central lymph node dissection to prevent the development of MTC.

What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?

Following surgery for medullary thyroid carcinoma, calcitonin levels may be used as a tumor marker for assessing disease recurrence. If a pheochromocytoma is the presenting malignancy in a patient who does not have a known MTC or hyperparathyroidism, fractionated plasma metanephrines may indicate the likelihood of MEN2A. Specifically, elevations in metanephrine (as opposed to isolated elevations in normetanephrine) are associated with NF1 and MEN2-related pheochromocytoma and may, therefore, be useful prior to the acquisition of genetic testing results. If a bilateral pheochromocytoma is surgically removed, it may be necessary to utilize laboratory measurements of adrenocortical hormones to guide replacement therapy and ensure that acute adrenal insufficiency does not occur.

Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?

As with all tumor markers measured by immunoassay, calcitonin measurements over time to detect disease recurrence should be performed by the same laboratory using the same assay whenever possible. If it is necessary to change laboratories and/or platforms, both the old and new assays should be performed on a crossover sample to rebaseline the patient.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs